

United States Flu Vaccine - Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2024

Latest Report on Flu Vaccine Market United States Analysis & 2024 Forecast Research Study

PUNE, INDIA, January 2, 2018 /EINPresswire.com/ -- United States Flu Vaccine Industry

United States flu vaccine market is expected to reach nearly US\$ 3 Billion by 2024. Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine.

Long-term Growth Projection and Development:

Sanofi to Acquire Protein Sciences Corporation

- It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024.
- Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season
- It is projected that GSK flu vaccine sales value will reach around US\$ 1.5 Billion by 2024
- BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine

Try Sample Report @ https://www.wiseguyreports.com/sample-request/1837352-flu-vaccine-market-outlook-2024-united-states-opportunity-and-demand-analysis

"Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024" provides a deep and thorough evaluation of the United States flu vaccine market. The report provides an in–depth analysis of the flu vaccination pattern in both Children and Adults in the United States. It also provides essential insights into flu vaccine production, price, consumption, supply, distribution, demand and specification. It also covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials and promising flu vaccines in the clinical development. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.

The report concludes with the profiles of major players in the US flu vaccine market such as Sanofi Pasteur, GSK and Seqirus. The major market players are evaluated on various parameters such as company overview, product outlook, latest development & trends and sales analysis of flu vaccine market from 2011 to 2022. The report also entails major drivers and inhibitors in the US flu vaccine market.

Key Topics Covered in the Report

Market Overview: United States Flu Vaccine Market (2010 – 2024)

- United States Number of Persons Vaccinated with Flu Vaccine (2010 2024)
- United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification

- Reimbursement & Regulatory System in the US Flu Vaccine Market
- Mergers, Acquisitions, Key Agreements & Collaborations
- Promising Flu Vaccine in Clinical Development
- Flu Vaccine Clinical Trial Insights by Phase, Company & Country
- Key Drivers and Inhibitors of the US Flu Vaccine Market
- Key Companies Analysis

Major Flu Vaccines Covered Under This Report Are:

Fluzone High-Dose

- Fluzone Quadrivalent
- Intradermal (ID) Trivalent
- Vaxigrip
- Fluarix Quadrivalent
- Flulaval Quadrivalent
- Flucelvax Quadrivalent
- Afluria Quadrivalent
- Agrippal
- Fluad
- Fluvirin
- Fluvax

Key Companies Covered in This Report:

Segirus

- Sanofi Pasteur
- GlaxoSmithKline(GSK)

For Detailed Reading Please visit WiseGuy Reports @

https://www.wiseguyreports.com/reports/1837352-flu-vaccine-market-outlook-2024-united-states-opportunity-and-demand-analysis

Some Major Points from Table of content:

Executive Summary

Market Overview: United States Flu Vaccine Market (2010 – 2024)

United States Number of Persons Vaccinated with Flu Vaccine (2010 – 2024)

- 3.1 Number of Children Vaccinated
- 3.2 Number of Adults Vaccinated

Key Drivers and Inhibitors of the United States Flu Vaccine Market

- 4.1 Market Drivers
- 4.2 Market Inhibitors

United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification

- 5.1 Flu Vaccine Price Trends
- 5.1.1 Pediatric Flu Vaccine Price Trends
- 5.1.2 Adult Flu Vaccine Price Trends
- 5.2 United States Flu Vaccine Production, Supply, and Allocation (By Companies)
- 5.3 United States Flu Vaccine Distribution & Demand
- 5.4 Flu Vaccine Effectiveness
- 5.5 Managing Flu with Rapid Diagnostic Testing
- 5.6 Distribution Method of Flu Vaccination

United States Flu Vaccine Market – Reimbursement & Regulatory System

- 6.1 Reimbursement System
- 6.2 Regulation System

Market Dynamics – Mergers, Acquisitions, Key Agreements & Collaborations

- 7.1 Merger & Acquisitions
- 7.2 Collaboration Deal
- 7.3 Licensing, Exclusive & Distribution Agreement Deal
- 7.3.1 Licensing Agreement
- 7.3.2 Exclusive Agreement
- 7.3.3 Distribution Agreement

Flu Vaccine – Promising Vaccine in Clinical Development

- 8.1 Quadrivalent Seasonal Influenza VLP Vaccine
- 8.2 VN 100
- 8.3 Seasonal Influenza VLP Vaccine
- 8.4 M-001

Flu Vaccine – Clinical Trial Insights by Phase, Company & Country

- 9.1 Year 2017
- 9.2 Year 2016

Continued.....

For more information or any query mail at sales@wiseguyreports.com

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

Norah Trent

+1 646 845 9349 / +44 208 133 9349

Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.